 |
|
FLEX TECHNOLOGY FOR SYNTHESIS OF FULL-LENGTH GENE LIBRARIES: FLEX Technology for synthesizing full-length cDNA libraries - This patented technology utilizes poly-T priming followed by a reversible tailing procedure at the 5' end of single-strand cDNA to increase the representation of full-length double-stranded cDNAs from control rates of 10-20% to FLEX rates of 50-70%. This patent formed the basis for formation of Alphagene, Inc., a genomics company formed in 1993 and based in Boston , MA . • Scheele, G. and Fukuoka , S.-I. Synthesis of full-length, double-stranded DNA from a single-stranded linear DNA template. Patent no. 5,162,209, issued on 11-10-92. • Scheele, G. Synthesis of full-length double-stranded DNA from a single-stranded linear DNA template. Patent no. 5,643,766, issued on 7-1-97. PDF File - Flex Description BICARBONATE TREATMENT FOR CYSTIC FIBROSIS: While conducting scientific research at Harvard Medical School , my laboratory determined the ultimate biochemical deficiency in Cystic Fibrosis and published the mechanism of this deficiency in the exocrine pancreas in a number of scientific publications. Detailed information on these discoveries appear in this website under "Scientist" and "Pancreatic Dysfunction in Cystic Fibrosis is Due to Impairments in Bicarbonate Secretion". • Scheele, G. Treatment of pulmonary conditions associated with insufficient secretion of surfactant. Patent no. 5,863,563, issued on 1-26-99. This patent is held by Dr. George A. Scheele, the inventor. Slide Presentation - Pancreatic Dysfunction in Cystic Fibrosis A METHOD FOR DIAGNOSING PANCREATITIS A method for diagnosing pancreatitis, which measures Glycoprotein-2 (GP2) in the serum. • Scheele, G. and Fukuoka , S.I. A method for diagnosing pancreatitis. Patent no. 5,663,315, issued on 9-2-97. TOPICAL PREVENTION AND EARLY TREATMENT OF VIRAL INFECTIONS : Under the leadership of Dr. George A. Scheele, La Jolla Biosciences, LLC, has filed for three patents in the United States , with corresponding international filings, which claim the use of topical beta cyclodextrins for viricidal treatment of envelope viruses on topical surfaces of the body thereby preventing viral entry into the body. Drs. James E.K. Hildreth (Johns Hopkins Medical Institutions) and George A. Scheele (President, La Jolla Biosciences, LLC) are listed as co-inventors in the following three patent applications: 1. Prophylaxis, Systemic & Topical Treatments, Vaccines:
SUMMARY OF CLAIMS: • Broad protection covering use of cholesterol sequestering agents to prevent or treat infection by envelop viruses, including HIV, HTLV, Herpes, Hepatitis, Influenza & Pox viruses • Oral & IV therapeutics • Oral, IV, ID, IM & SubQ vaccines • Topical treatment of viral diseases (Herpes and Influenza) on all epithelial surfaces. • Protection for (myco-) bacterial, fungus, protozoan and non-envelope viruses (prevention of intracellular uptake) • Extracorporeal treatment of envelope viruses. 2. Protection/Decontamination/Sanitation Formulations for the Health Care Industry:
SUMMARY OF CLAIMS: • Broad protection covering use of cholesterol sequestering agents to reduce or prevent dermal transmission of envelope viruses, including HIV, HTLV, Herpes, Hepatitis, Influenza, SARS and Pox viruses. • Protect Medical workers, blood handlers and soldiers. • Gloves with an interior surface coated by BCD • Treating environmental surfaces • Uses of lotions, sprays and powders containing BCD. 3. Protection Technologies & Formulations for Blood Products:
SUMMARY OF CLAIMS: • Addition of cholesterol-sequestering agents to whole blood, plasma, packed red blood cells, platelet concentrates, gamma globulin, purified plasma factors, albumin and factors VIII, IX and VIIA. • Render viral-infected cells incapable of production of viable or functional viral particles • Inhibit cells from uptake of envelop and non-envelope viruses • Destroy free viral particles • Filtration of 2-HP-BCD treated white blood cells • Application of 2-HP-BCD to the blood circulation, cervical and vaginal canals to prevent envelope and non-envelope virus infection during childbirth to prevent maternal-to-fetal transmission of viruses. |
|
 |